Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine vs Gemcitabine + Docetaxel in Leiomyosarcoma
NCT00227669Phase 2Completed
- Sponsor
- Unicancer
- Start
- Oct 2005
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel in uterine leiomyosarcoma (uLMS) and soft tissue leiomyosarcoma (LMS) (2 arms), sponsored by Unicancer. Primary endpoint: Objective Response Rate at 6 months. Started Oct 2005; status: completed.
02
Drugs
docetaxel
03
Conditions
uterine leiomyosarcoma (uLMS)soft tissue leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT00227669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00227669.